Search our Innovation Portfolio

The Phase 3 project has been the catalyst for Noctura 400 (non-invasive, home based treatment for Diabetic Retinopathy) evaluation within the NHS. It has also initiated complimentary evaluation for early stage disease intervention in a primary care Optometry setting. Noctura 400 exposure has been increased as a result and as such has stimulated significant adoption interest from both patient groups and eye care professionals.

The N-Tidal device is a high-resolution capnometer that records carbon dioxide levels during 75 seconds of relaxed, normal breathing through a mouthpiece. It transfers that data via 4G to TidalSense’s cloud platform where biomarkers are generated. AI-derived algorithms are then applied to those biomarkers for a variety of use-cases such as the diagnosis of COPD or asthma. The time from breath to diagnostic or monitoring result is under five minutes, allowing N-Tidal to be used as a point of care test. This pilot will evaluate how best this technology can be used to help children with asthma/wheeze.

BioEP is a tool to help clinicians diagnose epilepsy. It uses data from routine EEG tests to create a computational model of the brain. Using the model, BioEP can indicate the ability of the brain to produce epileptic seizure activity and therefore indicate whether BioEP supports a diagnosis of epilepsy or not.

BioEP adds additional information and can be particularly useful when EEGs do not capture any information that is helpful in supporting a diagnosis of epilepsy. BioEP has the potential to speed up reaching an accurate diagnosis and we hope this will help people with suspected epilepsy.